Factors for Incidence Risk and Prognosis of Synchronous Brain Metastases in Pulmonary Large Cell Carcinoma Patients: a Population-based Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Jan 12

PMID 36635639

Authors

Xuan Zheng

Shuai Mu

Lijie Wang

Haitao Tao

Di Huang

Ziwei Huang

Xiaoyan Li

Pengfei Cui

Tao Li

Qingyan Liu

Yi Hu

Affiliations

Soon will be listed here.

Abstract

Background: Patients with pulmonary large cell carcinoma (LCC) have a high incidence of synchronous brain metastases (SBM) and a poor prognosis. Our study was to evaluate the predictive and prognostic value of the clinical characteristics of pulmonary LCC patients with SBM at initial diagnosis by utilizing the Surveillance, Epidemiology, and End Results (SEER) database.

Methods: LCC patients, diagnosed from 2010 to 2019, were identified from the latest SEER database which was released in April 2022. Logistic regression and Cox regression were used to identify the predictive and prognostic factors for LCC patients with SBM. Propensity score matching (PSM) and Kaplan-Meier analyses were applied to assess different therapy modalities.

Results: A total of 1375 LCC patients were enrolled in this study and 216 (15.7%) of them had SBM at the initial diagnosis. The median overall survival (OS) of LCC patients with SBM was 4 months. Multivariate Cox regression identified age 60-79 (OR 0.57; 95% CI 0.41-0.78; p < 0.001), age ≥ 80 (OR 0.23; 95% CI 0.12-0.45; p < 0.001) and bone metastases (OR 1.75; 95% CI 1.22-2.51; p < 0.001) as significant independent predictors for developing SBM. Multivariable Cox regression revealed that age 60-79, T stage, bone metastases and chemotherapy were independent prognostic factor for OS. The surgery combined with chemotherapy and radiotherapy group, in which all patients were N0 stage and had no other site-specific metastases, exhibited the best median OS of 15 months.

Conclusions: LCC patients with age < 60 or bone metastases were more likely to have SBM at initial diagnosis. Age, T stage, bone metastases and chemotherapy were independent prognostic factors for OS of LCC patients with SBM. Highly selected patients might achieve the best survival benefit from surgery combined with chemotherapy and radiotherapy.

Citing Articles

Efficacy of Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost (SIB-WBRT) for Lung Cancer Brain Metastases.

Bi Q, Shen J, Li P, Zeng Y, Lian X, Zhang F J Cancer. 2024; 15(14):4636-4642.

PMID: 39006075 PMC: 11242338. DOI: 10.7150/jca.95804.

Exploration of radiotherapy strategy for brain metastasis patients with driver gene positivity in lung cancer.

Bi Q, Lian X, Shen J, Zhang F, Xu T J Cancer. 2024; 15(7):1994-2002.

PMID: 38434971 PMC: 10905398. DOI: 10.7150/jca.91875.

References

Pelosi G, Barbareschi M, Cavazza A, Graziano P, Rossi G, Papotti M . Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. Lung Cancer. 2015; 87(3):226-31. DOI: 10.1016/j.lungcan.2015.01.008. View

Sperduto P, Mesko S, Li J, Cagney D, Aizer A, Lin N . Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020; 38(32):3773-3784. PMC: 7655019. DOI: 10.1200/JCO.20.01255. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(5):497-530. DOI: 10.6004/jnccn.2022.0025. View

Zhu H, Zhou L, Guo Y, Yang G, Dong Q, Zhang Z . Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study. Future Oncol. 2021; 17(19):2461-2473. DOI: 10.2217/fon-2021-0103. View

Ashworth A, Senan S, Palma D, Riquet M, Ahn Y, Ricardi U . An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014; 15(5):346-55. DOI: 10.1016/j.cllc.2014.04.003. View

Rekhtman N, Travis W . Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity. J Thorac Oncol. 2019; 14(7):1125-1127. DOI: 10.1016/j.jtho.2019.04.014. View

Waqar S, Samson P, Robinson C, Bradley J, Devarakonda S, Du L . Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin Lung Cancer. 2018; 19(4):e373-e379. PMC: 6990432. DOI: 10.1016/j.cllc.2018.01.007. View

Wu A, Gossa S, Samala R, Chung M, Gril B, Yang H . Aging and CNS Myeloid Cell Depletion Attenuate Breast Cancer Brain Metastasis. Clin Cancer Res. 2021; 27(15):4422-4434. PMC: 9974011. DOI: 10.1158/1078-0432.CCR-21-1549. View

Shin D, Na I, Kim C, Park S, Baek H, Yang S . EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014; 9(2):195-9. DOI: 10.1097/JTO.0000000000000069. View

10.

Kumar S, Wang X, Pittell H, Calip G, Weiss S, Meyer J . Real-world Use of Radiation for Newly Diagnosed Brain Metastases in Patients With ALK-positive Lung Cancer Receiving First-line ALK Inhibitor. Int J Radiat Oncol Biol Phys. 2022; 114(4):627-634. DOI: 10.1016/j.ijrobp.2022.07.010. View

11.

Wang X, Wang Z, Pan J, Lu Z, Xu D, Zhang H . Patterns of Extrathoracic Metastases in Different Histological Types of Lung Cancer. Front Oncol. 2020; 10:715. PMC: 7248315. DOI: 10.3389/fonc.2020.00715. View

12.

Wood S, Pernemalm M, Crosbie P, Whetton A . The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2013; 40(4):558-66. DOI: 10.1016/j.ctrv.2013.10.001. View

13.

Lim S, Lee J, Lee M, Kim H, Lee J, Sun J . A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Ann Oncol. 2014; 26(4):762-768. DOI: 10.1093/annonc/mdu584. View

14.

Popper H . Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016; 35(1):75-91. PMC: 4821869. DOI: 10.1007/s10555-016-9618-0. View

15.

Mrdjen D, Pavlovic A, Hartmann F, Schreiner B, Utz S, Leung B . High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity. 2018; 48(2):380-395.e6. DOI: 10.1016/j.immuni.2018.01.011. View

16.

Xu Z, Yang Q, Chen X, Zheng L, Zhang L, Yu Y . Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study. Oncol Lett. 2019; 17(6):5590-5600. PMC: 6507334. DOI: 10.3892/ol.2019.10225. View

17.

Nikolich-Zugich J . The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2017; 19(1):10-19. DOI: 10.1038/s41590-017-0006-x. View

18.

Wrona A, Dziadziuszko R, Jassem J . Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Cancer Treat Rev. 2018; 71:59-67. DOI: 10.1016/j.ctrv.2018.10.011. View

19.

Travis W, Brambilla E, Burke A, Marx A, Nicholson A . Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015; 10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. View

20.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View